ACOG — Alpha Cognition Inc

Summary of Alpha Cognition Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Revenue: Total revenue of $2.8 million, with net product revenues of $2.5 million from ZUNVEYL.
• Full Year 2025 Revenue: Total revenue of $10.2 million, including $6.8 million from ZUNVEYL.
• Operating Loss: Q4 operating loss of $7.9 million, compared to $2.7 million in Q4 2024. Full year operating loss was $22.7 million, up from $12 million in 2024.
• Net Loss: Q4 net loss of $6.9 million ($0.30 per share), compared to a net loss of $5.8 million ($0.52 per share) in Q4 2024. Full year net loss was $20.7 million ($1.17 per share), compared to $14.8 million ($2.04 per share) in 2024.
• Cash Position: As of December 31, 2025, the company had approximately $66 million in unrestricted cash.

2. Strategic Updates and Business Highlights

• ZUNVEYL Launch: Continued sales growth and demand expansion, particularly in long-term care. Q4 saw 4,941 bottles dispensed, a 62% increase quarter-over-quarter.
• Payer Access: Secured contracts with 2 of the top 4 national pharmacy benefit managers (PBMs), enhancing market access.
• Clinical Studies: Announced three real-world studies (BEACON, CONVERGE, RESOLVE) set to provide data on ZUNVEYL's efficacy and tolerability, with results expected in late 2026.
• Sales Force Expansion: Completed expansion of the sales team to enhance market penetration and support peer-to-peer education initiatives.

3. Forward Guidance and Outlook

• 2026 Expectations: While no formal revenue guidance was provided, the company anticipates continued sequential growth in ZUNVEYL sales and expects operating expenses to range between $54 million and $58 million, primarily due to clinical studies and sales initiatives.
• Path to Profitability: The company aims for operational profitability by 2027, supported by a strong cash position and strategic initiatives.

4. Bad News, Challenges, or Points of Concern

• Operating Losses: Significant increase in operating losses year-over-year raises concerns about sustainability without revenue growth.
• Payer Access Challenges: Although contracts with PBMs have been secured, the company faces challenges in ensuring smooth access and reducing prior authorization friction, which could hinder sales growth.
• Market Competition: The competitive landscape in Alzheimer's treatments remains a concern, particularly as ZUNVEYL seeks to establish itself in a market with established players.

5. Notable Q&A Insights

• Payer Conversion Timing: Management expects some acceleration in payer adoption in Q2 2026, with broader implementation anticipated in Q3.
• Clinical Development Focus: The CONVERGE study will evaluate polypharmacy impacts, which could be crucial for positioning ZUNVEYL in the market. The BEACON study aims to demonstrate ZUNVEYL's efficacy in cognitive and behavioral symptom management.
• Sublingual Formulation: Plans to advance a sublingual formulation for patients with dysphagia, with potential market entry in 2027, leveraging existing sales infrastructure.
• Sales Strategy: The company is shifting its marketing focus to emphasize behavioral benefits of ZUNVEYL, which resonates strongly with prescribers, particularly in long-term care settings.

This summary encapsulates the key points from the earnings call, providing a balanced view of Alpha Cognition's current performance and future direction.